FDA breakthrough designation for Bayer and Merck & Co’s AI softwareBayer and Merck & Co have won a breakthrough device designation from the US regulator FDA for artificial Share XFDA breakthrough designation for Bayer and Merck & Co’s AI softwarehttps://pharmaphorum.com/news/fda-breakthrough-designation-bayer-merck-ai/
NHS funds BMS’ Opdivo to prevent skin cancer returningNICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer Share XNHS funds BMS’ Opdivo to prevent skin cancer returninghttps://pharmaphorum.com/news/nhs-funds-bms-opdivo-to-prevent-skin-cancer-returning/
AstraZeneca’s immunotherapy fails in key lung cancer trialAstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line Share XAstraZeneca’s immunotherapy fails in key lung cancer trialhttps://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-key-lung-cancer-trial/
Merck & Co begins US filing of Ebola vaccineMerck & Co has begun a rolling filing in the US of its Ebola Zaire vaccine, known as Share XMerck & Co begins US filing of Ebola vaccinehttps://pharmaphorum.com/news/merck-co-begins-us-filing-of-ebola-vaccine/
BMS and Infinity trial immunotherapy combo in bladder cancerBristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the Share XBMS and Infinity trial immunotherapy combo in bladder cancerhttps://pharmaphorum.com/news/bms-and-infinity-trial-immunotherapy-combo-in-bladder-cancer/
Keytruda approved for combination lung cancer therapyThe US Food and Drug Administration (FDA) has approved Merck & Co’s Keytruda plus chemotherapy as a first-line Share XKeytruda approved for combination lung cancer therapyhttps://pharmaphorum.com/news/keytruda-approved-for-combination-lung-cancer-therapy/
AZ/Merck & Co’s Lynparza scores huge ovarian cancer winAstraZeneca and Merck & Co’s Lynparza (olaparib) has massively reduced the risk of BRCA-mutated ovarian cancer progressing in Share XAZ/Merck & Co’s Lynparza scores huge ovarian cancer winhttps://pharmaphorum.com/news/az-merck-cos-lynparza-scores-huge-ovarian-cancer-win/
Roche’s Tecentriq posts trial wins in two key indicationsRoche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple Share XRoche’s Tecentriq posts trial wins in two key indicationshttps://pharmaphorum.com/news/roches-tecentriq-posts-trial-wins-in-two-key-indications/
BMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientsBristol-Myers Squibb’s Opdivo and Yervoy combination could become first line treatment for a small group of metastatic colorectal Share XBMS’ Opdivo+Yervoy could become first choice for certain colorectal cancer patientshttps://pharmaphorum.com/news/bms-opdivoyervoy-could-become-first-choice-for-certain-colorectal-cancer-patients/
